• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于配体和基于结构的虚拟筛选方法在聚(ADP-核糖)聚合酶-1 抑制剂上的系统比较。

Systematic comparison of ligand-based and structure-based virtual screening methods on poly (ADP-ribose) polymerase-1 inhibitors.

机构信息

Xiangya School of Pharmaceutical Sciences, Central South University, P. R. China.

Xiangya Hospital, Central South University, P. R. China.

出版信息

Brief Bioinform. 2021 Nov 5;22(6). doi: 10.1093/bib/bbab135.

DOI:10.1093/bib/bbab135
PMID:33940596
Abstract

The poly (ADP-ribose) polymerase-1 (PARP1) has been regarded as a vital target in recent years and PARP1 inhibitors can be used for ovarian and breast cancer therapies. However, it has been realized that most of PARP1 inhibitors have disadvantages of low solubility and permeability. Therefore, by discovering more molecules with novel frameworks, it would have greater opportunities to apply it into broader clinical fields and have a more profound significance. In the present study, multiple virtual screening (VS) methods had been employed to evaluate the screening efficiency of ligand-based, structure-based and data fusion methods on PARP1 target. The VS methods include 2D similarity screening, structure-activity relationship (SAR) models, docking and complex-based pharmacophore screening. Moreover, the sum rank, sum score and reciprocal rank were also adopted for data fusion methods. The evaluation results show that the similarity searching based on Torsion fingerprint, six SAR models, Glide docking and pharmacophore screening using Phase have excellent screening performance. The best data fusion method is the reciprocal rank, but the sum score also performs well in framework enrichment. In general, the ligand-based VS methods show better performance on PARP1 inhibitor screening. These findings confirmed that adding ligand-based methods to the early screening stage will greatly improve the screening efficiency, and be able to enrich more highly active PARP1 inhibitors with diverse structures.

摘要

聚 ADP-核糖聚合酶 1(PARP1)近年来被视为一个重要的靶点,PARP1 抑制剂可用于卵巢癌和乳腺癌的治疗。然而,人们已经意识到,大多数 PARP1 抑制剂的溶解度和渗透性较低。因此,通过发现更多具有新型结构的分子,将有更大的机会将其应用于更广泛的临床领域,并具有更深远的意义。在本研究中,采用了多种虚拟筛选(VS)方法来评估基于配体、基于结构和数据融合方法对 PARP1 靶标的筛选效率。VS 方法包括 2D 相似性筛选、构效关系(SAR)模型、对接和基于复合物的药效团筛选。此外,还采用了总和秩、总和评分和倒数秩进行数据融合方法。评估结果表明,基于扭转指纹的相似性搜索、六个 SAR 模型、Glide 对接和使用 Phase 的药效团筛选具有出色的筛选性能。最佳的数据融合方法是倒数秩,但总和评分在框架富集方面也表现良好。总的来说,基于配体的 VS 方法在 PARP1 抑制剂筛选中表现出更好的性能。这些发现证实,在早期筛选阶段加入基于配体的方法将大大提高筛选效率,并能够富集更多具有不同结构的高活性 PARP1 抑制剂。

相似文献

1
Systematic comparison of ligand-based and structure-based virtual screening methods on poly (ADP-ribose) polymerase-1 inhibitors.基于配体和基于结构的虚拟筛选方法在聚(ADP-核糖)聚合酶-1 抑制剂上的系统比较。
Brief Bioinform. 2021 Nov 5;22(6). doi: 10.1093/bib/bbab135.
2
Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking and Biological Evaluation for Identification of Potential Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors.基于结构的药效团模型构建、虚拟筛选、分子对接及生物评价鉴定潜在的多聚(ADP-核糖)聚合酶-1(PARP-1)抑制剂。
Molecules. 2019 Nov 22;24(23):4258. doi: 10.3390/molecules24234258.
3
A review on PARP1 inhibitors: Pharmacophore modeling, virtual and biological screening studies to identify novel PARP1 inhibitors.聚(ADP-核糖)聚合酶1(PARP1)抑制剂综述:用于鉴定新型PARP1抑制剂的药效团建模、虚拟筛选和生物学筛选研究
Curr Top Med Chem. 2014;14(17):2020-30. doi: 10.2174/1568026614666140929152123.
4
Crystal structure-based discovery of a novel synthesized PARP1 inhibitor (OL-1) with apoptosis-inducing mechanisms in triple-negative breast cancer.基于晶体结构发现一种新型合成的PARP1抑制剂(OL-1)及其在三阴性乳腺癌中的凋亡诱导机制
Sci Rep. 2016 Dec 5;6(1):3. doi: 10.1038/s41598-016-0007-2.
5
Probing PARP1-inhibitor complexes for the development of novel inhibitors.探索PARP1抑制剂复合物以开发新型抑制剂。
Cell Mol Biol (Noisy-le-grand). 2014 Oct 25;60(3):43-52.
6
Design, synthesis and evaluation of potential inhibitors for poly(ADP-ribose) polymerase members 1 and 14.设计、合成和评估多聚(ADP-核糖)聚合酶成员 1 和 14 的潜在抑制剂。
Future Med Chem. 2020 Dec;12(24):2179-2190. doi: 10.4155/fmc-2020-0218. Epub 2020 Nov 23.
7
Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.聚 ADP-核糖聚合酶 1(PARP1)抑制剂作为抗癌药物的药物化学方法 - 最新进展。
Eur J Med Chem. 2019 Mar 1;165:198-215. doi: 10.1016/j.ejmech.2019.01.024. Epub 2019 Jan 12.
8
Leveraging shape screening and molecular dynamics simulations to optimize PARP1-Specific chemo/radio-potentiators for antitumor drug design.利用形状筛选和分子动力学模拟优化 PARP1 特异性化疗/放疗增敏剂用于抗肿瘤药物设计。
Arch Biochem Biophys. 2024 Jun;756:110010. doi: 10.1016/j.abb.2024.110010. Epub 2024 Apr 18.
9
Design, synthesis, and biological evaluation of novel chrysin derivatives as poly(ADP-ribose) polymerase 1 (PARP1) inhibitors for the treatment of breast cancer.新型白杨素衍生物的设计、合成及作为聚(ADP-核糖)聚合酶 1(PARP1)抑制剂用于治疗乳腺癌的生物学评价。
Chin J Nat Med. 2024 May;22(5):455-465. doi: 10.1016/S1875-5364(24)60642-4.
10
Discovery of isoquinolinone and naphthyridinone-based inhibitors of poly(ADP-ribose) polymerase-1 (PARP1) as anticancer agents: Structure activity relationship and preclinical characterization.发现异喹啉酮和萘啶酮类聚(ADP-核糖)聚合酶-1(PARP1)抑制剂作为抗癌剂:结构活性关系和临床前特征。
Bioorg Med Chem. 2020 Dec 15;28(24):115819. doi: 10.1016/j.bmc.2020.115819. Epub 2020 Oct 14.

引用本文的文献

1
InertDB as a generative AI-expanded resource of biologically inactive small molecules from PubChem.InertDB作为一种通过生成式人工智能扩展的来自PubChem的生物无活性小分子资源。
J Cheminform. 2025 Apr 10;17(1):49. doi: 10.1186/s13321-025-00999-1.
2
ChemMORT: an automatic ADMET optimization platform using deep learning and multi-objective particle swarm optimization.ChemMORT:一个使用深度学习和多目标粒子群优化算法的自动 ADMET 优化平台。
Brief Bioinform. 2024 Jan 22;25(2). doi: 10.1093/bib/bbae008.
3
Multimodal data fusion for supervised learning-based identification of USP7 inhibitors: a systematic comparison.
基于监督学习的USP7抑制剂识别的多模态数据融合:系统比较
J Cheminform. 2023 Jan 11;15(1):5. doi: 10.1186/s13321-022-00675-8.
4
Therapeutic and prognostic potential of GPCRs in prostate cancer from multi-omics landscape.基于多组学格局探究G蛋白偶联受体在前列腺癌中的治疗和预后潜力
Front Pharmacol. 2022 Aug 30;13:997664. doi: 10.3389/fphar.2022.997664. eCollection 2022.